SENSORCAINE

Post-LOE

bupivacaine hydrochloride

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

May 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

SENSORCAINE (bupivacaine hydrochloride) by Fresenius Kabi is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1986.

Drug data last refreshed 20h ago

Mechanism of Action

impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…

Indications (7)

regional anesthesia analgesia for surgery

Worked on SENSORCAINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.